Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRL-02 depot in advanced prostate cancer
NCT04729114Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2021
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of abiraterone decanoate in prostate cancer (PCa) (5 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 4 years and 7 more. Started Jun 2021; status: recruiting.
02
Drugs
abiraterone decanoate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04729114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729114.